Sequenom (SQNM) : 3 days before expiry, shorts in Sequenom (SQNM) have reduced from 8,332,951 on Jul 29, 2016, to 5,647,697 on August 15, 2016. On an average, 2,235,350 shares are traded on the exchange. The outstanding bearish positions are equal to 4.8% of the float. Short sellers have covered -2,685,254 shares, a reduction of -32.2%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Sequenom (NASDAQ:SQNM): The stock opened at $2.38 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.39 for the day. The stock traded down to $2.38 during the day, due to lack of any buying support eventually closed down at $2.39 with a loss of -0.21% for the day. The stock had closed at $2.39 on the previous day. The total traded volume was 1,565,825 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the CFO of Sequenom Inc, Beaver Carolyn had purchased shares worth of $33,000 in a transaction dated on June 10, 2016. A total of 30,000 shares were purchased at a price of $1.1 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.